An Israeli company is formulating the first “cannaceutical” aiming to help people with insomnia and other sleep disorders
The product, called ican.sleep, is a “cannaceutical” (pharmaceutical-grade cannabis product) that is lined up to be launched in the global market following patient trials taking place in Q3 this year.
According to the two companies jointly releasing the product, CannRx and iCAN:Israel-Cannabis, ican.sleep will utilise pharmaceutical-grade delivery systems to provide a stable, controlled dose of cannabis formulation.
It will use a CannRx proprietary technology called CannTrap to capture and stabilise cannabinoids that are “soluble and adequately bioavailable”.
The companies say the product will “rapidly induce sleep with a prolonged ‘through the night’ therapeutic effect”.
Says Saul Kaye, Australian ex-pat and co-founder of iCAN Israel-Cannabis: “As an insomniac myself I am proud to be involved in bringing a next generation cannabis product to the market. Doseable, repeatable cannabis is a reality.”
Research shows that cannabis, like alcohol, may improve subjective sleep complaints, particularly when used over short periods of time.
However, chronic cannabis use has also been associated with negative subjective effects on sleep, especially during withdrawal. This includes withdrawal effects among people exposed to low dosages.
CannRx explains that its technology will provide the benefit of lower doses with increased and prolonged effects, as well as a reduction of side effects.
“[We have] designed unique and proprietary delivery systems for medical cannabis that increase bioavailability, reduce carcinogenicity, and provide precise dosing of cannabis-based medicines,” it says.